ArticleBioconjugate chemistry2016
Synthesis, Characterization, and Application of Core-Shell Co0.16Fe2.84O4@NaYF4(Yb, Er) and Fe3O4@NaYF4(Yb, Tm) Nanoparticle as Trimodal (MRI, PET/SPECT, and Optical) Imaging Agents.
Article in Bioconjugate chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Challenges in Controlled Doping of NaMnFACS omega · 2026Article
- Multimodal imaging in cancer detection: the role of SPIONs and USPIONs as contrast agents for MRI, SPECT, and PET.Future oncology (London, England) · 2025Review
- Nuclear Nanomedicines: Utilization of Radiolabelling Strategies, Drug Formulation, Delivery, and Regulatory Aspects for Disease Management.Current radiopharmaceuticals · 2025Review
- [Molecules (Basel, Switzerland) · 2024Review
- Functional Diversity in Radiolabeled Nanoceramics and Related Biomaterials for the Multimodal Imaging of Tumors.ACS bio & med chem Au · 2023Review
- Dual-Labelling Strategies for Nuclear and Fluorescence Molecular Imaging: Current Status and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Multimodal Contrast Agent Enabling pH Sensing Based on Organically Functionalized Gold Nanoshells with Mn-Zn Ferrite Cores.Nanomaterials (Basel, Switzerland) · 2022Article
- In vivo optical molecular imaging of inflammation and immunity.Journal of molecular medicine (Berlin, Germany) · 2021Review
- Design and Synthesis of Luminescent Lanthanide-Based Bimodal Nanoprobes for Dual Magnetic Resonance (MR) and Optical Imaging.Nanomaterials (Basel, Switzerland) · 2021Review
- Alteration of the Mitochondrial Effects of Ceria Nanoparticles by Gold: An Approach for the Mitochondrial Modulation of Cells Based on Nanomedicine.Nanomaterials (Basel, Switzerland) · 2020Article
- Polyol-Made Luminescent and Superparamagnetic β-NaYNanomaterials (Basel, Switzerland) · 2020Article
- Core-Shell NaHoFACS applied materials & interfaces · 2019Article
- Multimodality Imaging Agents with PET as the Fundamental Pillar.Angewandte Chemie (International ed. in English) · 2019Review
- Applications of nanoparticles in biomedical imaging.Nanoscale · 2019Review
- Article
- Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities.Biomaterials · 2018Article
- Role of MnNanomaterials (Basel, Switzerland) · 2018Article
- Synthesis, Radiolabelling and In Vitro Imaging of Multifunctional Nanoceramics.ChemNanoMat : chemistry of nanomaterials for energy, biology and more · 2018Article
- PET-MR and SPECT-MR multimodality probes: Development and challenges.Theranostics · 2018Review
- Radiolabeled inorganic nanoparticles for positron emission tomography imaging of cancer: an overview.The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
Multimodal nanoparticulate materials are described, offering magnetic, radionuclide, and fluorescent imaging capabilities to exploit the complementary advantages of magnetic resonance imaging (MRI), positron emission tomography/single-photon emission commuted tomography (PET/SPECT), and optical imaging. They comprise Fe3O4@NaYF4 core/shell nanoparticles (NPs) with different cation dopants in the shell or core, including Co0.16Fe2.84O4@NaYF4(Yb, Er) and Fe3O4@NaYF4(Yb, Tm). These NPs are stabilized by bisphosphonate polyethylene glycol conjugates (BP-PEG), and then show a high transverse relaxivity (r2) up to 326 mM(-1) s(-1) at 3T, a high affinity to [(18)F]-fluoride or radiometal-bisphosphonate conjugates (e.g., (64)Cu and (99m)Tc), and fluorescent emissions from 500 to 800 nm under excitation at 980 nm. The biodistribution of intravenously administered particles determined by PET/MR imaging suggests that negatively charged Co0.16Fe2.84O4@NaYF4(Yb, Er)-BP-PEG (10K) NPs cleared from the blood pool more slowly than positively charged NPs Fe3O4@NaYF4(Yb, Tm)-BP-PEG (2K). Preliminary results in sentinel lymph node imaging in mice indicate the advantages of multimodal imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.